Recently, our team has reported that TIPRL works as a drug-resistant modulator in HCCs via suppressing the MKK7/JNK and the subsequent caspase pathways [3] and accelerates the stemness of liver cancer cells by upregulating the expression of LC3 and CD133 [8]. The gene discussed is MAPK8; the disease is liver cancer.